The FTSE 100 pharmaceutical giant has listed on the NYSE after delisting American Depositary Shares from Nasdaq, whilst maintaining its London and Stockholm listings
Pharmaceutical heavyweight AstraZeneca has secured a listing on the New York Stock Exchange as part of its push for expanded international presence. The British drugs manufacturer is making the switch by delisting its American Depositary Shares from the Nasdaq exchange.
AstraZeneca commenced NYSE trading on Monday after it stopped trading ADS and certain debt securities on the Nasdaq after the end of Friday trading. The FTSE 100 company will retain its positions on both the London Stock Exchange and Nasdaq Stockholm.
Management told investors the fresh listing should enable American shareholders to benefit from the firm’s “strong growth” trajectory.
AstraZeneca generates nearly half its turnover in the US and is eyeing additional expansion in the globe’s biggest pharmaceutical marketplace.
Last July, the business outlined ambitions for around 50 billion US dollars (£36.5 billion) worth of investment by 2030.
The move follows closely on the heels of the group’s announcement of a collaboration with China’s CSPC Pharmaceutical Group to accelerate development of experimental obesity and diabetes treatments in an arrangement valued at 18.5 billion US dollars (£13.4 billion).
Through the agreement, the FTSE 100 drugs giant will secure exclusive worldwide rights, excluding China, to CSPC’s monthly dosing technology range for weight control, providing more practical alternatives to daily injections. Michel Demare, chairman of AstraZeneca, said: “Today marks the start of an exciting new period for AstraZeneca, one which we believe gives broader access to the largest capital market in the world.
“This will allow even more investors to participate in AstraZeneca’s future.
“Our harmonised listing across New York, London and Stockholm reflects strong shareholder support for our growth strategy and positions AstraZeneca to deliver more innovative medicines to more patients around the world.”
Lynn Martin, president of NYSE Group, said: “Today we are proud to welcome AstraZeneca to the NYSE, where it joins a community of ground-breakers and industry leaders.
“Through its listing on the world’s largest and most liquid capital market, the company is well-positioned to expand its global investor base and accelerate its commitment to delivering innovation to patients and the wider biopharmaceutical industry.”








